2022
DOI: 10.1016/j.ucl.2022.07.003
|View full text |Cite
|
Sign up to set email alerts
|

Current Management and Controversies Surrounding Andropause

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 65 publications
0
1
0
Order By: Relevance
“…et al, 2022 ), lowers the risk of breast cancer (in Korea) ( Baek et al, 2022 ), and reduces COVID-19 deaths ( Sund et al, 2022 ). Testosterone replacement therapy (TRT) is recommended for late-onset hypogonadism in aging males over 65 years old ( Nieschlag, 2020 ; Burte et al, 2021 ), but it is still a subject of controversy ( Diokno, 2022 ; Mian et al, 2022 ). Regardless of testosterone levels, most symptomatic late-onset hypogonadism has been shown not to be correlated ( Li et al, 2020c ; Ishikawa et al, 2020 ; La Vignera et al, 2020 ; Tsuru et al, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…et al, 2022 ), lowers the risk of breast cancer (in Korea) ( Baek et al, 2022 ), and reduces COVID-19 deaths ( Sund et al, 2022 ). Testosterone replacement therapy (TRT) is recommended for late-onset hypogonadism in aging males over 65 years old ( Nieschlag, 2020 ; Burte et al, 2021 ), but it is still a subject of controversy ( Diokno, 2022 ; Mian et al, 2022 ). Regardless of testosterone levels, most symptomatic late-onset hypogonadism has been shown not to be correlated ( Li et al, 2020c ; Ishikawa et al, 2020 ; La Vignera et al, 2020 ; Tsuru et al, 2022 ).…”
Section: Discussionmentioning
confidence: 99%